Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Bausch Health Companies Inc.    BHC   CA0717341071

BAUSCH HEALTH COMPANIES INC.

(BHC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Bausch Health : Pandemic cuts into Bausch Health sales as company posts US$152-million loss

share with twitter share with LinkedIn share with facebook
05/07/2020 | 05:06pm EDT

MONTREAL — Shares of Bausch Health Companies Inc. fell more than eight per cent as the company lowered its 2020 forecast after a loss in in the first quarter due to the COVID-19 pandemic.

The Quebec-based pharmaceutical and medical device company dropped its outlook by nearly 10 per cent, with expectations for revenue at about US$8 billion from US$8.75 billion and adjusted earnings at roughly US$3.25 billion from US$3.6 billion.

The move comes as Bausch reports a first-quarter loss of US$152 million, compared to a net loss of US$52 million a year earlier.

The company, which reports in U.S. dollars, cites decreased sales across most segments as well as higher expenses and litigation charges.

Bausch says revenue remained relatively flat at $2.01 billion in the quarter ended March 31 versus $2.02 billion in 2019, with the pandemic accounting for a $35-million loss.

Adjusted earnings reached 90 cents per share compared to $1.02 per share last year, slightly beating analyst expectations of 87 cents per share, according to financial markets data firm Refinitiv.

This report by The Canadian Press was first published May 7, 2020.

Companies in this story: (TSX:BHC)

© 2020 The Canadian Press. All rights reserved., source Canadian Press DataFile

share with twitter share with LinkedIn share with facebook
Latest news on BAUSCH HEALTH COMPANIES IN
06/24BAUSCH HEALTH : Ortho dermatologics announces arazlo lotion, 0.045%, now availab..
AQ
06/24BAUSCH HEALTH COMPANIES INC : . - Ortho Dermatologics Launches ARAZLO Lotion, 0...
AQ
06/23BAUSCH HEALTH : Ortho Dermatologics Launches ARAZLO™ (tazarotene) Lotion, ..
AQ
06/18BAUSCH HEALTH : + LOMB ULTRA Silicone Hydrogel Contact Lenses Receive Approval i..
AQ
06/11BAUSCH HEALTH : Health Canada Issues Notice of Compliance for Bausch Health's DU..
AQ
06/09EXCLUSIVE : Chanel, Revlon, L'Oreal pivoting away from talc in some products
RE
06/09EXCLUSIVE : Chanel, Revlon, L'Oreal pivoting away from talc in some products
RE
06/05BAUSCH HEALTH : FDA Provides 510(k) Clearance For BAUSCH + LOMB INFUSE Daily Dis..
AQ
05/28BAUSCH HEALTH : + Lomb Announces The European Launch Of LuxSmart And LuxGood Pre..
AQ
05/26BAUSCH HEALTH COMPANIES INC. : Entry into a Material Definitive Agreement, Creat..
AQ
More news
Financials (USD)
Sales 2020 8 043 M - -
Net income 2020 -407 M - -
Net Debt 2020 22 174 M - -
P/E ratio 2020 -15,3x
Yield 2020 -
Capitalization 6 506 M 6 506 M -
EV / Sales 2019
EV / Sales 2020 3,57x
Nbr of Employees 21 700
Free-Float 99,4%
Chart BAUSCH HEALTH COMPANIES INC.
Duration : Period :
Bausch Health Companies Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAUSCH HEALTH COMPANIES IN
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 28,00 $
Last Close Price 18,34 $
Spread / Highest target 249%
Spread / Average Target 52,7%
Spread / Lowest Target -7,31%
EPS Revisions
Managers
NameTitle
Joseph C. Papa Chairman & Chief Executive Officer
Paul S. Herendeen Chief Financial Officer & Executive Vice President
Tage Ramakrishna Chief Medical Officer, President-R&D
Robert N. Power Independent Director
David Robert Hale Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
BAUSCH HEALTH COMPANIES INC.-38.70%6 506
JOHNSON & JOHNSON-3.36%371 399
ROCHE HOLDING AG4.71%295 898
MERCK & CO., INC.-13.38%198 849
NOVARTIS AG-10.36%192 057
PFIZER, INC.-11.92%191 697